Market Research Blog – Page 13612 – New Product Development

New-Born Screening Equipment Market to Witness Excellent Revenue Growth, Overview, Emerging Trends and Forecast by 2026

Newborn Screening also called Neonatal Screening is a procedure to detect certain harmful, genetic, developmental or metabolic disorders that may result in mental retardation or death if not detected. In some cases the symptoms or signs are not present but disorder can be detected therefore the screening is done so as to avoid the certain conditions that eventually could cause problems and treatment can be offered right on time to avoid outcomes of untreated conditions. Newborn screening includes a blood test, hearing screening and screening for critical congenital heart defects they are conducted to diagnose disorders such as newborn hearing loss, cystic fibrosis, maple syrup urine disease, congenital hypothyroidism, critical congenital heart disease, sickle cell disease and congenital adrenal hyperplasia. Screening is done within a few days of birthor before leaving the hospital and in some countries there is second screening done at 1-2 weeks of age.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/new-born-screening-equipment-market

The global newborn screening market is categorized on the basis of technology, test type, product, and geography. The market is driven by factors such as benefits offered after newborn testing programs, advanced technology which help in introducing innovative devices, government initiative by providing funds and prevalence of newborn diseases. The rising Asian region and approach of next-generation sequencing technology are liable to offer prospects for newborn screening market to grow.

New-born Screening Equipment Market: Drivers and Restraints

Factors contributing to the growth of newborn screening equipment market includes the rise to incidence of newborn diseases, increasing awareness among the population base results in growth of market, rise in demand for newborn diagnosis, technological advancements to propel the growth of the market, market is growing as new entrants entering the market and government initiatives to bolster the growth of the market

However factors such as socio economic factors tremendously affect the market, lack of trained professionals and lack of healthcare infrastructure may hinder the growth of the market

New-born Screening Equipment Market: Overview

With rising incidence of diseases, rapid innovations in technology in medical field, and government initiative in spending for research and development, the newborn screening equipment market is expected to have tremendous growth during the forecast period (2016-2026).

New-born Screening Equipment Market: Region- wise Outlook

The global newborn screening equipment market is expected to grow at a faster rate during the forecast period. Depending on geographic regions, global newborn screening equipment market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

North America holds the largest share for newborn screening market due to growing prevalence and awareness of neonatal disorders, followed by Europe due to advancement in healthcare industry and expanded government support. On the other hand, Asia Pacific Market is showing an extremely positive development because of high rate of advancement in healthcare industry, rising prospects for new marketer and escalating government activity for the control of newborn diseases.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1221

New-born Screening Equipment Market: Key Players

Some of the key market players in global newborn screening equipment market are, Agilent Technologies, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare (India), and ZenTech S.A.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Eastern Europe)
Asia Pacific (China, India, ASEAN, Japan, Australia & New Zealand)
Latin America (Mexico, Brazil Others)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

New-born Screening Equipment Market: Segmentation

Global newborn screening equipment marketis segmented on the basis of products, test type and technology as following:

By Tests

Hearing Test
Blood Test
Cardiac Test
Urine Test

By Application

Hearing Disability
Blood Spot Disease
Critical Congenital Cardiac Disease
Sickle cells Disease
Thyroid Disorder
Maple Syrup Disease

By Product

Hearing Screening Devices
Pulse Oximetry
Mass Spectrometer
Assay Kits

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1221

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Biopsy Device Market is Growing & Expected to Reach US$ 3089.2 Million in the Time Period of 2022-2031

Over the 10-year forecast period 2021-2031, the global biopsy device market is estimated to witness a moderate yet promising CAGR of 5.2%, according to Future Market Insights. In a recently published report titled “Global Biopsy Device Market: Global Industry Analysis and Opportunity Assessment, 2021–2031” Future Market Insights analyses the market for biopsy device and offers key insights factors driving growth. Valued at around US$ 1,862.6 Mn in 2021, the market is forecast to surpass a valuation of US$ 3,089.2Mn by 2031-end.

Patients are increasingly preferring minimally invasive surgical procedures in order to avoid conventional surgical complications and side-effects, promoting sales of biopsy devices, leading to the growth of the biopsy devices globally. In addition to enabling the accurate diagnosis, a biopsy device assures minimal patient discomfort and trauma. This is identified to be a major factor impacting the popularity of biopsy, and biopsy device thereby.

Download the Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-1192

Key Opportunities for Manufacturers and Suppliers:

Developing economies present lucrative, untapped markets for biopsy device.
Growing adoption of hybrid imaging technology will underpin new growth opportunities.
Following massive consumption by hospitals, demand for biopsy device from specific oncology centers and research institutes will prompt at multiple opportunities in near future.
Surging demand for minimal invasive breast biopsy highlights lucrative opportunities that lie in the breast cancer sector.
Increasing adoption of biopsy device by oncologists will generate several revenue generation opportunities in the disease monitoring sector.

Supported by increasing discretionary funding for cancer research, growing government expenditure for healthcare and favorable reimbursement scenario (especially in the U.S.) will collectively elevate the revenue sales of the global biopsy device market. Collaborations between various government and private companies, fuelled by increasing awareness about disease diagnosis and monitoring, will further elevate the market growth in near future.

M&A and Technological Upgrades Remain at the Forefront

A majority of key players in the global biopsy device market are currently focusing on providing innovative biopsy tests and technological upgrades. Mergers, acquisitions, and partnerships with diagnostic laboratories will help to strengthen their presence in the global market.

Among the top companies, Becton, Dickinson and Company is concentrating on innovative, cost-effective product development, whereas Hologic, Inc. is targeting manufacture and sales of biopsy devices, especially for breast cancer surgeries. Other notable players include Boston Scientific Inc., C. R. Bard, Inc., B. Braun Melsungen AG, Cook Medical, INRAD Inc., and PLANMED OY.

Argon Medical, one of the promising new entrants, is expanding its product portfolio and collaborating with established players, whereas for Devicor Medical Products Inc., M&A remains the key strategy.

North America Remains the Most Lucrative Market

North America will remain the dominant market and is expected to surpass US$ 882 Mn by 2031 end, accounting for over 33% share of the market. Western Europe is expected to remain the second largest market for biopsy device, crossing a value of US$ 683 Mn by the end of 2031, capturing over 26% share of the market.

APEJ, with around 14% market value share in 2031, reaching a valuation of around US$ 370.0 Mn by the end of forecast period. MEA will register the fastest CAGR of 7.3%, followed by APEJ and Latin America with the respective CAGRs of 7.1% and 6.5% over 2021-2031. North America, Europe, and Japan will see moderate growth over the forecast period.

Biopsy Needles To Remain Top-selling Product Category

By product type, needles will remain dominant with over 36% share of the market value in 2031, whereas guns will represent the second largest sub-segment with over 26% market value share in 2031. With growing significance of early diagnosis of breast biopsy, guidance system segment is estimated to gain around 222 BPS in its market share by 2031 over 2021. Stereostatic X-ray guided biopsy will drive the guidance system segment through to 2031. Reagents and kits will witness moderate consumption.

Medical Diagnostics Monopolize Application Segment

Based on application type, medical diagnostics will continue to hold a dominant share of over 61% by 2031 end, in terms of revenues. Scientific research, accounting for the rest, will witness an impressively growing CAGR of 6.9% over 2021-2031. This segment is expected to reach beyond US$ 1,008.0 Mn in 2031.

Hospitals Remain Largest End-use Consumer

By end-user, hospitals will continue to contribute nearly 50% share to the market value by 2031 end. This end-use segment will witness a robust CAGR of 8.2%. Diagnostic centres will account for over 23% in 2031 with a slight decline over 2021-2031, whereas specialised oncology centres are anticipated to expand at a CAGR of 6.1% during 2021-2031.

Download the complete TOC of this Report: https://www.futuremarketinsights.com/reports/biopsy-device-market/table-of-content

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Wet Wipes Market is growing at a CAGR of 7.6% between the time period of 2021-2031

According to a recent study by Future Market Insights (FMI), the sales of wet wipes are expected to top US$ 3.7 Bn in 2021, growing at a CAGR of over 7.6% during the forecast period (2021-2031).

Increasing health-care related issues and the rising prevalence of infectious diseases and skin-related problems have increased concerns among general population. As a result, awareness with regards to the adoption of personal care and hygiene practices is at all-time high.

Regular usage of sanitizer, wet wipes, and tissues for cleanliness and maintaining proper hygiene has positively affected the wet wipes market. With various wet wipes options available in the market, catering to diverse purposes such as incontinence wet wipes- for urinary incontinence, sterile wound cleansing wet wipe- for cleaning wounds, and skin care wet wipe- for regular use; growth prospects for future remains optimistic.

Click to get the Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-13751

Traditionally, products such as soap, face wash, cleansing milk, and others which are already available in the market have been in use for personal hygiene for generations. But factors such as easy handling, convenience while travelling, achieving cleanliness of hand and face without using water have buoyed consumer inclination in favor of wet wipes.

Companies specializing in wet wipes have been focusing on developing more innovative products such as fragrance- filled wet wipes, environment-friendly, and biodegradable wet wipes and using wood pulp and cotton to avoid harmful effect on sensitive skin.

Government as well as private companies are involved in specialized marketing campaigns to address the need for wet wipes. Furthermore, mergers, acquisitions and collaboration are undertaken by companies to increase the product portfolio as well as reach. All these factors are expected to create demand for wet wipes.

Key takeaways from Wet wipes Market study

By product, incontinence wipes constitute the most lucrative segment in terms of revenue. The demand for incontinence wipes is expected to increase at a CAGR of over 7% 2021-2031.
By disposability, non-flushable wipes segment will hold a revenue share of around 75% in 2021 and is expected to follow the similar growth trend in the future.
By application, skin care wipes segment holds the largest share and will continue to dominate this segment in the forecast period.
In terms of end user, hospitals are leading the market and are expected to gain more than 25% of revenue share over the forecast period.
North America will dominate the global wet wipes market in terms of revenue in 2021, followed by Europe region.
India is dominating the South Asia wet wipes market, accounting for nearly 29% of global market share in 2021.
China holds leading position in East Asia and is expected to account for nearly 40% of market share.

“Steered by changing consumer preference, market players are rethinking sources of materials used for wet wipes manufacturing. Their focus is shifting towards more sustainable and biodegradable options to reduce the burden of wet wipes disposal on the environment. This will present attractive opportunities for growth of the market in the near future,” said a lead FMI analyst.

Who is winning?

Some of the leading manufacturers of wet wipes are focusing on innovative product launches, specialized marketing campaigns, mergers, acquisitions and partnership strategies, thereby enhancing their market presence.

In February 2018, Procter & Gamble Co. announced the acquisition of Snowberry, a New Zealand-based skincare company which specialized in natural ingredient products.
In August 2020, Kimberly-Clark’s brand Pull-Ups launched a product, New Leaf™. Pull-Ups® New Leaf™ is made with plant-based ingredients like sugarcane and fluff pulp, carefully selected and crafted to provide the high level of protection.
In February 2018, Stryker completed the acquisition of Entellus Medical, a medical technology company and strengthen Stryker’s personal care product portfolio.

The key market players covered by FMI include Essity Aktiebolag (publ), Kimberly-Clark, Procter & Gamble, Cardinal Health, Medtronic, Stryker, Coloplast, Hindustan Unilever Ltd., Medline Industries Inc., ConvaTec Inc., The Himalaya Drug Company, Domtar Corporation, Johnson & Johnson Private Limited, Hollister Incorporated and Godrej Consumer Products Limited.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global wet wipes market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on wet wipes segment based on Product (incontinence wipes, Skin Antiseptic wipes, Feminine Hygiene wipes, Skin Care wet wipes and Sterile Wound Cleansing wipes), Disposability (Flushable wipes and Non-Flushable wipes), Application (Incontinence, Skin Care, Personal Hygiene and Wound Care) and End User (Hospitals, Clinics, Speciality Centres, Long Term Care Centres and Homecare settings) across seven major regions.

Click to get the complete TOC of this Report: https://www.futuremarketinsights.com/reports/wet-wipes-market/table-of-content

About the Healthcare Division at Future Market Insights

Advance Wound Care Market is expected to register a CAGR of 3.7% during the forecast period 2021-2031

According to a recent study by Future Market Insights (FMI), the advance wound care market is expected to grow from US$ 10.7 Bn in 2021 to US$ 15.4 Bn by 2031. The market is poised to expand at a CAGR of 3.7% over the forecast period (2021-2031).

Rising prevalence of chronic wounds has created a significant socioeconomic impact. The treatment of chronic wounds requires advance wound care therapies and generally takes long time to heal. The prevalence of diabetic ulcers is rising by 9% annually.

Asked for this Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-13947

Growing patient pool for diabetic foot ulcer is increasing as compared to the available advance wound care management technologies. Currently, there are more than 4.5 million pressure ulcer patients in the world that require treatment.

More than 9.7 million venous ulcer patients and roughly 10.0 million diabetic ulcer patients require treatment across the world. Annually, over 5 million chronic leg ulcer cases occur in Brazil, while approximately 2.7 million chronic leg ulcer cases occur in Mexico.

Hence, with rising need for advance wound care products for the treatment of various chronic disorders, adoption within hospitals and ambulatory surgical centers is expected to increase. Thereby, bolstering market growth.

Number of pressure and venous ulcer patients has grown from approx. 7% in developed countries, such as the U.S., Germany, and the U.K., which is further expected to drive the growth of the market for advance wound care products.

Focus on collaboration with surgeons for better wound management, improvement and streamlining of regulatory processes and inter and intra-departmental collaboration between surgeons and their support staff for wound management plays a key role in ensuring better wound management and promotes the growth of the advance wound care market.

Key Takeaways from Advance Wound Care Market Study

By product, wound cleansers segment is likely to grow at a CAGR of 4.6% in the projected period, occupying a market share around 30% by 2031.
By distribution channel, the institutional sales are projected to capture over 70.2% market share of the global advance wound care market by 2031.
North America is the largest revenue-generating region for the global advance wound care market, with the U.S. accounting for nearly 90% market share in 2031.
China is expected to spearhead the growth in East Asia advance wound care market and is poised to expand at an impressive pace of 7.0% CAGR over the decade.
East Asia is the third most lucrative market, acquiring a market share of more than 15%, for the advance wound care market.

“Increasing prevalence of chronic wounds and growing awareness towards adoption of medical treatment across the globe will propel the market growth over the next ten years,” says the FMI Analyst

Who is Winning?

Some of the leading manufacturers of advance wound care market are focusing on product launch and expansion strategies for global expansion objectives, thereby, enhancing their market presence.

In June 2021, Mölnlycke started a new surgical glove factory in Malaysia to increase its production capacity. The new surgical glove reduces the risk of allergic contact dermatitis for surgeons and nurses.
In Feb 2021, Coloplast A/S launched Biatain® Fiber portfolio to contribute positively to the market’s growth in France and Germany. Technology is an absorbent gelling fiber, for highly exuding wounds, sloughy wounds and cavity wounds including undermining and facilitates autolytic debridement and desloughing which promotes the wound healing process.
In June 2021, Ethicon Inc. launched the ENSEAL X1 Curved Jaw Tissue Sealer, a new advance after-surgery wound healer. It’s a Bipolar energy device increases procedural efficiency and provides stronger sealing of wound.

The key market players covered by FMI include B. Braun Melsungen AG, Mölnlycke Health Care, ConvaTec Group plc, Coloplast A/S, Johnson and Johnson, Medline Industries Inc., 3M, QIAGEN N.V, Essity AB (BSN Medical), Smith and Nephew plc, BOENMED, Hakuzo Medical Asia Co. Ltd.

Asked for the Complete TOC of this Report: https://www.futuremarketinsights.com/reports/advance-wound-care-market/table-of-content

About the Healthcare Division at Future Market Insights

Needle-Free Injectors Market Overview & Analysis by Load Liquid Injections, Powder Injections, Projectile Injections-Forecast to 2022-2031

According to a latest study by Future Market Insights (FMI), global needle-free injectors’ sales are expected to reach US$ 12.3 Bn in 2021, surging at 11.4% CAGR during the forecast period (2021-2031)

Needle-free injection is an innovative drug delivery technology that drives drugs to the skin using force which virtually nullifies the use of hypodermic needle. With growing preference for non-invasive drug delivery system and vaccines, adoption of needle-free injectors is expected to improve over the coming years

Request for the Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-13960

Application of needle-free injectors is increasing with rising incidence of diabetes and other chronic diseases across the globe. With increasing number of surgeries, demand for minimally invasive procedures is accelerating the sales of needle-free injectors.

According to Centers for Disease Control and Prevention (CDC), more than 51% of adults in U.S. had at least 1 chronic condition, and 27.2% had multiple chronic conditions in 2018.

Other factors driving the global demand are cost-effectiveness and safety related to needle-free injectors.

Key Takeaways from Needle-free Injectors Market study

By load type, liquid injections segment will hold around 88.0% of value share globally.
Based on the technology, spring-loaded jet injector is dominating the market, with over 48.0% of the market share.
Based on the delivery site, intra dermal injector is expected to hold over 33% of the market share.
Application of drug delivery will spur the sales of needle-free injectors, with the segment accounting for 65% of the market share.
Based on the usage, reusable needle free injectors are highly sought-after, contributing over 78% of the market revenue.
Hospitals are expected to be the primary end-users, holding a market share of 28% during the forecast period.
By region, North America will dominate the global needle-free injectors market, holding 42% of total market share.
Europe is expected to be the second-largest market, with Germany spearheading the market growth .
India will emerge as the most lucrative market across South Asia, accounting for nearly 50% of market share in 2021.
China will hold leading position in East Asia and is expected to account for nearly 46% of market share.

“Growing prevalence of chronic diseases coupled with rising preference of non-invasive drug delivery system will improve the adoption of needle-free injectors. With rising demand for needle-free injectors, key players are introducing new product launches and are aiming for fast track approvals to capitalize on existing opportunities and sustain their position in the industry “says the FMI Analyst.

Who is Winning?

New product launches and approvals, agreements, and collaborations are some of the key growth strategy adopted by the key players. By focusing on these strategies, key players intend to expand their global presence and strengthen their existing product portfolio.

For instance,

In November 2019, Antares Pharma collaborated with Idorsia for the development of a novel self-administered drug-device product.
In June 2020, Vitaeris Inc., a biotech company was acquired by CSL Limited. The acquisition was carried out by CSL Limited to achieve the motive of addressing the unmet needs of patients.

The key market players covered by FMI include Pfizer, Inc., Gerresheimer AG, Ferring Pharmaceuticals, CSL Limited (Seqirus UK Limited) and others.

Request for the complete TOC of this Report: https://www.futuremarketinsights.com/reports/needle-free-injectors-market/table-of-content

About the Healthcare Division at Future Market Insights

Generic Injectable Market to rise at 11.6 % CAGR through the end of the forecast period in 2031.

The Global Generic Injectable market study provides critical information related to the global, regional and top players including Generic Injectable market share analysis, winning strategies, recent developments, and financial planning. Besides providing information regarding the key players in the Generic Injectable market, the study also recalibrates, the impact of macroeconomic and microeconomic factors that has the potential to impact the growth of the Generic Injectable market.

Over the past decade, healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.

Understanding the Impact of Covid-19 on Healthcare Industry

With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance.

The FMI’s latest report on the Generic Injectable market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-6051

Reasons to Buy the report

We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Detailed analysis on the geographical region and country wise insights are offered in the latest Generic Injectable market report with established market players as well as incumbents in the region.

The global Generic Injectable market can be segmented as follows:

Monoclonal antibody generic injection possible
Immunoglobulin generic injection
Cytokine generic injection
Insulin generic injection
Peptide hormone generic injection
Blood factor generic injection
Peptide antibiotic generic injection
Vaccine generic injection
Generic injection of small molecule antibiotics
Chemotherapeutic agent General injection

Any Queries About Report, Contact Us @ https://www.futuremarketinsights.com/askus/rep-gb-6051

Molecular type

Small molecule generic injection
Polymer generic injection

application

Oncology Generic Injection
Infectious diseases General injection
Diabetes general injection
Hematopoietic system general injection
Hormonal diseases General injections
Musculoskeletal disorder General injection possible
Central nervous system diseases General injection possible
Pain management generic injection
General injections for cardiovascular disease

Route of administration

Intravenous (IV) generic injection
Intramuscular (IM) generic injection
Subcutaneous (SC) generic injection

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

Competitive Analysis

By Prominent Market Players:

Samsung Biologics Co., Ltd.
Aurobind Pharma Limited
Sun Pharma Japan Limited
Novartis AG
Merck & Co. Inc.
Cipla Ltd
Pfizer Japan Inc
Fresenius Kabi
Sanofi SA
AstraZeneca Plc
Teva Pharmaceuticals.
Mylan NA
Baxter International
Dr. Reddy’s Laboratories Ltd

With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Generic Injectable market

Request For Table of Content @ https://www.futuremarketinsights.com/toc/rep-gb-6051

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies
Detailed insights of market segments and sub-segments for historical as well as forecast period
A competitive analysis of prominent players and emerging players in the Generic Injectable market
Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Industrial Microbiology Market is exhibiting a CAGR at 4.95% during the forecast period 2021-2031

Key Takeaways from FMI’s Industrial Microbiology Market Study

Pharmaceutical industry is anticipated to be the primary end-user of industrial microbiology market
Sterility testing is the most preferred test type among the key players backed by the increased application in pharmaceutical industry
Increasing application of industrial microbiology in food & beverages is expected to foster the sales, especially across the U.S. and India
In terms of product, reaction consumables is expected to lead the segment over the forecast period
India is expected to emerge as a lucrative market owing to the expansion of healthcare industry and growing application in pharmaceutical industry
Germany is anticipated to be the most lucrative country, accounting for over 31% of global market share
China is anticipated to lead the East Asia’s market during the forecast period, registering a stellar growth during the assessment period
The U.S. is estimated to be the largest market for industrial microbiology market attributed to the growing consumers demand and surge in adoption of sterility testing in pharmaceutical industry

ESOMAR-certified consulting firm Future Market Insights’ (FMI’s) report forecasts the global industrial microbiology market to exhibit steady growth, surpassing a valuation of US$ 13,3072.73 Mn by 2021-end.

Growing application of industrial microbiology within pharmaceutical and food & beverage industry across China, the U.S., Germany and India will bolster the demand of industrial microbiology across the globe.

As per the FMI’s analysis, the industrial microbiology market across the U.S. and India is anticipated to expand at an impressive rate over the forecast period.

Growing adoption of sterility and bio-burden testing within pharmaceutical industry will foster the sales of industrial microbiology products.

Increasing research and development activities along with the increasing drug development within biopharmaceutical industry across the U.S., France, and India will bolster the market growth in the upcoming decade.

Increasing applications in pharmaceutical excipients have encouraged the adoption of sterility and bio-burden testing for the quality testing of drugs and micro-organisms. However, dearth of skilled labor and high cost production is likely to hamper the growth of industrial microbiology.

Due to unprecedented outbreak of COVID-19, sales of industrial microbiology declined by 1.95%, exhibiting a CAGR at 4.95% during the forecast period.

However, with rising initiatives to reduce the pollution and improve the wastewater treatment efficiency, industrial microbiology market valuation will reach US$ 21,566.24 Mn by 2031.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1743

“Key players are increasing research & development activities to facilitate drug discovery and food testing within the pharmaceutical & food industry. This, in turn, is likely to widen growth opportunities for the market players over the coming years,” says the FMI analyst.

Competitive Landscape

Future Market Insights, in its updated report, have profiled prominent players operating in industrial microbiology market which include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Asiagel Corporation, Eppendorf AG, bioMérieux SA, Novamed., QIAGEN, Sartorius AG, 3M, Merck KGaA and Danaher Corporation among others.

Manufacturers of industrial microbiology systems are actively focusing on expanding their product portfolios to improve their revenue generation.

As per FMI, the market is dominated by top players such as Thermo Fisher Scientific Inc. and BioMerieuxx Inc. making the market consolidated.

Targeted mergers and collaborations with top healthcare and pharmaceutical companies is anticipated to be the key strategy to maintain their top position in the industry.

New product launches with the expansion of their existing product range is one of the common market strategy for the key players. For instance:

In March 2020, leading player, Danaher Corporation announced the acquisition of the biopharma business from the Life Sciences Division of General Electronics. With this acquisition, the company has been renamed as Cytiva and will be functioning as a standalone company within the Danaher Corporation.

More Insights on the Global Industrial Microbiology MarketFuture Market Insights, in its latest report, offers an incisive coverage on the global industrial microbiology market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is classified on the basis of product type (equipment and systems, reaction consumables, and others), test type (sterility testing, microbial limits testing, and bio-burden testing), and end user (pharmaceutical & biotechnology, food & beverages, agriculture & environmental, and personal care products) across seven major regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Industrial microbiology Market by CategoryBy Product Type:

Equipment and Systems
- Filtration Pumps and Systems
- Microbial Detection Systems
- Air Monitoring Systems
- Automated Equipment
- Incubators and Culture Apparatus
- Others
Reaction Consumables
- Media
- Simple Media
- Complex Media
- Defined Media
- Specialty Media
- Reagents and Strains
Others
- Laboratory Supplies
- Bags and Bottles
- Loop and Needles
- Petri Dishes, Racks, Seals, Plates and Holders
- Filtration Disc and Membranes
- Others

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1743

By End User:

Pharmaceuticals and Biotechnology
Food and Beverages
Agriculture and Environmental
Personal Care Products

By Test Type:

Sterility Testing
Microbial Limits Testing
Bio-burden Testing

By Region:

North America
Latin America
Western Europe
Eastern Europe
Japan
Asia Pacific excluding Japan (APEJ)
Middle East & Africa (MEA)

Drugs of Abuse Testing Market is growing at above 5% CAGR over the forecast period to 2021 – 2031

As per a recent market analysis by Future Market Insights, the global drug of abuse testing market is projected to top US$ 1.5 Bn in 2021, expanding at over 5% CAGR over the forecast period.

Growth can be attributed to the increasing opioid dependence in the geriatric population as a result of high dosage prescription opioid use for pain management. Chronic pain is prevalent among patients suffering from arthritis, heart diseases, and cancer Opioids are prescribed for pain management, however, overdose can result in fatalities.

In response to this, manufacturers are launching rapid, accurate, disposable, and easy-to-use drug of abuse testing kits to detect drug dependence among the elderly. This is indicative of lucrative prospects for new market entrants over the assessment period.

Besides this, growing acceptance of recreational marijuana also has triggered concerns regarding overdose. Marijuana addiction is rare, although overdose can result in breathing disorders, memory loss, elevated stress and anxiety, and concentration issues. As a result, demand for drug of abuse testing systems in corporate and educational organizations is rising for early detection of substance abuse.

As per FMI’s in-depth regional analysis, the U.S. is projected to dominate the North America drug of abuse testing market. The presence of robust healthcare infrastructure along with the prevalence of an opioid endemic in the country is expected to continue pushing sales of drug of abuse testing tools.

“The introduction of integrated drug warning systems that monitor drug overdose in real-time is expected to fuel sales of drug abuse testing equipment. Besides this, increasing adoption of drug testing tools in forensic laboratories to identify illicit drugs for the criminal justice system are expected to continue augmenting growth of the global drug of abuse testing market through 2031,” says an FMI analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1649

Competitive Landscape

Quest Diagnostics, Roche Holding AG, Thermo Fisher Scientific, Inc., Siemens AG (Siemens Healthineers), Abbott Laboratories (Alere, Inc.), Shimadzu Corporation, Express Diagnostics International Inc., Drägerwerk AG & Co. KGaA, and Laboratory Corporation of America Holdings are among the key players profiled by FMI.

Leading players operating in the global drug of abuse testing market are focusing on research and development to expand their product portfolios. Besides this, players are aiming at production facility expansions through mergers, acquisitions, and collaborations.

Key Takeaways:

Based on drug type, sales of drug of abuse testing for cannabinoids are expected to remain high through 2031.
In terms of technique, immunoassays will remain highly sought-after.
Demand for drug of abuse testing in forensic laboratories is anticipated to continue gaining traction over the assessment period.
The U.S. is projected to dominate the North America drug of abuse testing market owing to increasing prevalence of opioid dependence in the country.
The U.K. will continue exhibiting high demand for drug of testing systems in response to government initiatives regarding drug awareness and control measures.
China will emerge as an attractive market due to the presence of key market players and easy availability of raw materials for the manufacturing of testing products.
Japan will account for 7% of the total drug of abuse testing market share, while South Korea is expected to hold less than 1% of the total market share through 2031.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1649

Drug of Abuse Testing Market by Category

By Drug Type:

Psychostimulants
Narcotic
Cannabinoids
Sedatives
Others

By Technique:

Immunoassay
Chromatography
Rapid Testing

By End User:

Hospitals
Diagnostics Laboratories
Forensic Laboratories
Others

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/1649

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

Surgical Generators Market totaling a valuation of US$ 570 Million by 2028

[148 Pages Report] The global surgical generators market is estimated to hit the US$ 421.5 Million cap in 2021, expanding at a moderate year-on-year growth of 3.2 percent, during the same period. As per a recent market study by Future Market Insights, the global market for surgical generators is expected to represent an absolute dollar opportunity of US$ 161.65 Million, through the forecast period considering in the study, 2022-2028. Electrosurgical Radiofrequency (RF) generators, in terms of product type, are expected to pump maximum revenue into the global surgical generators market, holding a market share of approximately 49.4 percent. However, Argon Plasma Coagulation generators have shown significant adoption in recent years, as per the study, translating into a substantial market share in the coming years. Its application in haemostasis, tissue devitalization, tissue reduction, and for rapid surgical ablation solutions, using ultra precision are some key factors driving the Argon Plasma Coagulation generators segment, according to the study.

FMI predicts moderately growing demand for surgical generators, considering:

Increased technological innovations aimed at providing efficient electrosurgery and associated deices. Moreover, operating rooms have evolved substantially, in the recent years, mostly equipped with technologies offering high efficiency and productivity.
Compatibility capabilities offered by new-age surgical generation, with various ablation devices. Additionally, advancements in surgical generators have changed the minimal invasive surgeries (MIS) landscape.
Technologically advanced electrosurgical RF generators and ultrasonic generators have the ability to handle input variations for ablation devices and cautery, while also demonstrating the effectiveness, safety, accuracy of electrosurgical devices.
Furthermore, deployment of low-cost ablation devices versus those required in RF-based ablation techniques including bipolar and ultrasonic ablation device, have significantly reduced the maintenance and repair costs, thereby further reducing the cost of surgical generators.
Growing demand for plastic and cosmetic surgeries—all executed using various types of electrosurgical devices.
Moreover, most modern surgeries require devices that provide energy to tissue to perform desired task.
Growth of ambulatory surgical centers (ASCs) surgeries is considered a major factor for increased sales of surgical generators. Technologically advancements and market consolidation have immensely supported ASCs—now carrying out critical procedures including maxillofacial, hip, spine and laparoscopic surgeries.

Attribute	Details
Estimated Surgical Generators Market Size 2022	US$ 467.2 Mn
Surgical Generators Market Value-based CAGR (2022-2028)	~3.4%
Projected Surgical Generators Market Size in 2028	US$ 570 Mn

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-663

surgical generators market

“However, given the complexities relating to surgical generators in operating rooms, there are some critical market restrainers that we have studies in the recent report on surgical generators. Mostly importantly, lack of skill and training of operating electrosurgical devices along with complications in electrosurgery and potential risks of burns, are the key market inhibitors, considering that the modern day operating rooms and procedure suites are sophisticated computer-driven control centers of highly complex “point-of-care” delivery. Unfamiliarity with the basis functioning of such devices could prove fatal, in the form of Operating Room (OR) fires. Moreover, complications of electrosurgery can occur in form of combustible gases explosions, accidental burns, interference with pacemakers and monitors, and infection transmission”, explained a senior analysts from the healthcare domain, while listing out the reasons for a slow-moving surgical generators market.

Surgical Generators Market Showcases a Relatively Concentrated Landscape with top leaders such as Bovie Medical Corporation, Ethicon (J&J), Olympus Corporation, CONMED Corporation, and Medtronic amongst others holding a market share of approximately 45 percent. Technological innovations combined with strategic mergers and acquisitions aimed at expanding product portfolio and improve patient safety and procedure accuracy, are anticipated to remain the core differentiation strategies among surgical generators manufacturers. Moreover, FMI also foresees increased investments in research and development activities, generating significant demand for surgical generators, mostly in hospitals, as per the study.

For instance, Olympus, a key players in the global surgical generators market, introduced its ESG-300 Electrosurgery Generator. The Argon Plasma Unit (APU-300) including the Olympus exclusive Smart Argon mode identifies distance to tissue and regulates power automatically. US Medical Innovations, in 2017, launched its advanced Smart Electrosurgical Generator Canady Plasma offering Graphical Interface Management Surgical System and Tissue Impedance Sensitive Control.

Surgical Generators Market by CategoryProduct Type:

Electrosurgical RF Generators
Electrocautery Generators
Ultrasonic Generators
Argon Plasma Coagulation Generators

End User:

Hospitals
Ambulatory Surgery Center
Specialty Clinics
Trauma Center

Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-663

Bioprocess Technology Market is expected to register a CAGR of 15.2% during the forecast period (2021-2031)

[245 Pages Report] According to a recent study by Future Market Insights (FMI), the global bioprocess technology market was valued at US$ 17.3 Bn in 2020 and is expected to register a CAGR of 15.2% during the forecast period (2021-2031). It is projected to generate a revenue of US$ 81.2 Bn by the end of 2031.

Technology has always been at the heart of biotech. The emergence of advanced computing technology such as machine learning and artificial intelligence has enabled companies to expand the scale of their research and improve efficiency in the manufacturing process—both of which reduce the time it takes for biotech firms to bring new products to market.

Increasing research and development spending on pharmaceutical products has improved the well-being of patients to a significant level. Today vaccines have proven to be one of the most effective ways to prevent children from infectious diseases. This is highly possible due to increased government spending on research & development in the life science stream.

For instance, in May 2020, AbSci Inc. closed USD 15.4 Mn in series D funding to accelerate the growth and scale of disruptive protein printing technology, by announcing an exclusive co-marketing partnership with KBI Biopharma.

There are currently more than 1,500 biomolecules undergoing clinical trials, which target more than 100 hundred types of diseases and success rate for biologics has so far been over twice that of small-molecule products.

Key Takeaways from Bioprocess Technology Market Study

In 2021, the BIOTECH/BIOPHARMACEUTICAL COMPANIES segment is expected to dominate the global bioprocess technology market with a 44.0% market share, whereas, CDMO/contract research organization segment is expected to occupy over 40% of the market share.
By product, the upstream segment dominated the global Bioprocess Technology market with a 64.8% market share.
Europe and East Asia dominated the global bioprocess technology market occupying over 24.3% and 14.7% market share, respectively.

“Single-use bioprocess products offer lucrative investment opportunities. With the increasing biopharmaceutical manufacturing across the world, adoption of single-use products is expected to gain traction,” says the FMI Analyst

bioprocess technology market key regions and end user mekko chart 2021

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13890

Who is winning?Some of the leading companies of bioprocess technology are focusing on their extensive portfolio of single-use cell culture bioreactors, containers, strong distribution channels, and strategic selling to the leading biopharmaceutical manufacturing entities.

Thermo Fisher Scientific Inc. is a multinational biotech company that develops, manufactures, and distributes products in the areas of healthcare & diagnostics, life sciences, pharmaceuticals, and others. In Sep 2020, Thermo Fisher Scientific Inc. announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.
Sartorius AG is a leading provider of contract testing services to the global biotechnology and biopharmaceutical industries. In July 2020, Sartorius Stedim Biotech acquired a majority stake in CellGenix to strengthen its product portfolio for cell and gene therapies.
Danaher Corporation designs manufacture and markets professional, medical, industrial, and commercial products and services. In March 2020 Danaher Corporation acquired the Biopharma business from General Electric’s Life Sciences division.

The key market players covered by FMI include Thermo Fisher Scientific Inc, Sartorius, Merck KGa, Danaher Corporation, Applikon Biotechnology B.V., Lonza AG, Bio-Rad Laboratories, Agilent technologies, Solida Biotech GmBH, and Waters Corporation.

Want more insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global bioprocess technology market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the bioprocess technology segment based on product type (upstream equipment, downstream equipment), end-users (biotech/biopharmaceutical companies, CDMO/contract research organization, research/academic institutes), and across seven major regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13890

Scope of the Report

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	USD Million for Value.
Key Countries Covered	US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa
Key Segments Covered	Product, End users, and Region
Key Companies Profiled	Thermo Fisher Scientific Inc Sartorius, Merck KGa Danaher Corporation (Pall Biotech and Cytiva) Merck KGaA STADA Arzneimittel AG Danaher Corporation Applikon Biotechnology B.V. (Getinge) Lonza AG Bio-Rad Laboratories Agilent technologies Solida Biotech GmBH Waters Corporation
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Bioprocess Technology Market by CategoryProduct:

Upstream Equipment
- Cell culture development products
  - Cell line development products
  - Cell Lines
  - Media, Sera and other additives
  - Cell line development kits
Lab-scale Bioreactors
- Continuous Stirred Tank Bioreactors
- Bubble Column Bioreactors
- Airlift Bioreactors
- Fluidized Bed Bioreactors
- Packed Bed Bioreactors
- Photo-Bioreactors

End-User:

Biotech/Biopharmaceutical Companies
CDMO/Contract Research Organization
Research/Academic Institutes

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/13890